Market Overview:
The global α-adrenoreceptor antagonists market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of hypertension, raynaud's disease, and erectile dysfunction. Additionally, the growing awareness about the benefits of α-adrenoreceptor antagonists is also contributing to the growth of this market. However, stringent regulatory requirements and side effects associated with these drugs are restraining the growth of this market. The global α-adrenoreceptor antagonists market can be segmented on the basis of type into non-selective antagonists and selective antagonists. The non-selective antagonist segment is expected to dominate this market during the forecast period owing to its low cost and high availability as compared to selective antagonist drugs. On the basis of application, this market can be divided into hypertension, raynaud's disease, and erectile dysfunction.
Product Definition:
α-adrenoreceptor antagonists are a class of medications that block the action of α-adrenergic receptors. They are used to treat conditions such as hypertension, congestive heart failure, and migraines.
Non-selective Antagonists:
Non-selective anticholinergic drugs are used to treat conditions such as urinary incontinence, congestive heart failure, and gastrointestinal disorders. The drug class includes atropine, scopolamine, and hyoscine; which are used in various medical applications.
Selective Antagonists:
A selective antagonist is a drug that binds to the receptor and blocks the action of naturally occurring endorphins, which are also known as opioid receptors. The binding of the drug to its receptor results in reduced agonist (activation) effects and blocked downstream (effect) effects. Some drugs are pure antagonists while some are mixed partial agonists-antagonists.
Application Insights:
The hypertension application segment led the global α-adrenoreceptor antagonists market in 2017. This is attributed to the rising prevalence of high blood pressure, which is a major public health concern. According to data published by WHO, more than 30 million people have hypertension worldwide. Moreover, as per the National Health Statistics Report 2016 released by U.S., around 29% of adults in America suffer from high blood pressure and this proportion increases with age group: 25-44 years and 45-64 years having around 34% and 32% respectively. Thus, increasing incidence of hypertension coupled with growing awareness about treatment options is expected to drive demand for these drugs over the forecast period 2o18–2030 ¢â‚¬Ëœ10%.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the local presence of key manufacturers, such as Pfizer Inc.; Merck & Co., Inc.; and Sanofi. Moreover, these players are engaged in extensive R&D activities for the development of novel drugs targeting “off-label†uses of “blockers off patentâ€. For instance, in May 2018, sanofi announced that it received a U.S FDA approval for its hypertension drug valsartan/hctz 12 50 mg/valsartan 80 mg film-coated tablets (Co-vid).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising healthcare expenditure and increasing prevalence rates of target diseases such as erectile dysfunction.
Growth Factors:
- Increasing prevalence of hypertension and other cardiovascular diseases: The global prevalence of hypertension is estimated to be around one billion, and this number is projected to increase to 1.5 billion by 2025. This will create a large pool of patients who will require treatment with α-adrenoreceptor antagonists, driving the market growth.
- Rising geriatric population: The global geriatric population is expected to grow from 524 million in 2010 to 1.6 billion by 2050, creating a large pool of patients who are at an increased risk for developing cardiovascular diseases and requiring treatment with α-adrenoreceptor antagonists.
- Technological advancements: The development of novel α-adrenoreceptor antagonists that are more efficacious and have fewer side effects is likely to drive the market growth in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
α-adrenoreceptor Antagonists Market Research Report
By Type
Non-selective Antagonists, Selective Antagonists
By Application
Hypertension, Raynaud's Disease, Erectile Dysfunction
By Companies
Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer, GSK, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global α-adrenoreceptor Antagonists Market Report Segments:
The global α-adrenoreceptor Antagonists market is segmented on the basis of:
Types
Non-selective Antagonists, Selective Antagonists
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hypertension, Raynaud's Disease, Erectile Dysfunction
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Merck
- Astra Zeneca
- Jhonson and Johnson
- Eli Lilly
- Sanofi
- Bristol-Myers Squibb
- Bayer
- GSK
- Pfizer
Highlights of The α-adrenoreceptor Antagonists Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Non-selective Antagonists
- Selective Antagonists
- By Application:
- Hypertension
- Raynaud's Disease
- Erectile Dysfunction
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the α-adrenoreceptor Antagonists Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
α-adrenoreceptor antagonists are medications that block the effects of α-adrenergic receptors. These drugs are used to treat a variety of conditions, including hypertension, angina, and heart failure.
Some of the major players in the î±-adrenoreceptor antagonists market are Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer, GSK, Pfizer.
The ±-adrenoreceptor antagonists market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 α-adrenoreceptor Antagonists Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 α-adrenoreceptor Antagonists Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 α-adrenoreceptor Antagonists Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the α-adrenoreceptor Antagonists Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global α-adrenoreceptor Antagonists Market Size & Forecast, 2020-2028
4.5.1 α-adrenoreceptor Antagonists Market Size and Y-o-Y Growth
4.5.2 α-adrenoreceptor Antagonists Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Non-selective Antagonists
5.2.2 Selective Antagonists
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hypertension
6.2.2 Raynaud's Disease
6.2.3 Erectile Dysfunction
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global α-adrenoreceptor Antagonists Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 α-adrenoreceptor Antagonists Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Non-selective Antagonists
9.6.2 Selective Antagonists
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hypertension
9.10.2 Raynaud's Disease
9.10.3 Erectile Dysfunction
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Non-selective Antagonists
10.6.2 Selective Antagonists
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hypertension
10.10.2 Raynaud's Disease
10.10.3 Erectile Dysfunction
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Non-selective Antagonists
11.6.2 Selective Antagonists
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hypertension
11.10.2 Raynaud's Disease
11.10.3 Erectile Dysfunction
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Non-selective Antagonists
12.6.2 Selective Antagonists
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hypertension
12.10.2 Raynaud's Disease
12.10.3 Erectile Dysfunction
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Non-selective Antagonists
13.6.2 Selective Antagonists
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hypertension
13.10.2 Raynaud's Disease
13.10.3 Erectile Dysfunction
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 α-adrenoreceptor Antagonists Market: Competitive Dashboard
14.2 Global α-adrenoreceptor Antagonists Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 Merck
14.3.4 Astra Zeneca
14.3.5 Jhonson and Johnson
14.3.6 Eli Lilly
14.3.7 Sanofi
14.3.8 Bristol-Myers Squibb
14.3.9 Bayer
14.3.10 GSK
14.3.11 Pfizer
